Anti-CD73
Showing 1 - 25 of >10,000
Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Trial in Boston (AGEN1423,
Not yet recruiting
- Advanced Pancreatic Ductal Adenocarcinoma
- +2 more
- AGEN1423
- +3 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Nov 18, 2022
Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer Trial in Marseille (IPH5301 ALONE OR IN COMBINATION
Recruiting
- Metastatic Cancer
- +8 more
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
-
Marseille, FranceInstitut Paoli Calmettes
Feb 23, 2022
Advanced or Metastatic Solid Tumors Trial in Australia (AK119, AK104)
Active, not recruiting
- Advanced or Metastatic Solid Tumors
- AK119
- AK104
-
Blacktown, New South Wales, Australia
- +4 more
Jan 5, 2023
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial
Recruiting
- Borderline Resectable Pancreatic Adenocarcinoma
- +5 more
- Durvalumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Solid Tumor Trial in Jinan (IBI325 + sintilimab, IBI325)
Active, not recruiting
- Solid Tumor
- IBI325 + sintilimab
- IBI325
-
Jinan, Shandong, ChinaShandong Province Cancer Hospital
Oct 10, 2022
Solid Tumor Trial (JAB-BX102 (anti-CD73 mAb), pembrolizumab (anti-PD-1 mAb))
Not yet recruiting
- Solid Tumor
- JAB-BX102 (anti-CD73 monoclonal antibody)
- pembrolizumab (anti-PD-1 monoclonal antibody)
- (no location specified)
Jul 19, 2022
Solid Tumor Trial in Jinan (IBI325+Sintilimab)
Not yet recruiting
- Solid Tumor
-
Jinan, Shandong, ChinaShandong Province Cancer Hospital
Feb 17, 2022
Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)
Recruiting
- Advanced Solid Tumor
- +18 more
- PT199
- Anti-PD-1 monoclonal antibody
-
Huntersville, North Carolina
- +2 more
Aug 10, 2022
Coronavirus Disease 2019 (COVID-19) Trial in Christchurch (AK119, Placebo)
Completed
- Coronavirus Disease 2019 (COVID-19)
- AK119
- Placebo
-
Christchurch, New ZealandChristchurch Clinical Studies Trust
Oct 15, 2021
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma Trial in Houston (Durvalumab,
Recruiting
- Metastatic Angiosarcoma
- +7 more
- Durvalumab
- Oleclumab
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2021
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
Advanced Solid Tumor Trial in Beijing (CD73 Antigen)
Recruiting
- Advanced Solid Tumor
- CD73 Antigen
-
Beijing, ChinaBeijing Cancer Hospital
Jul 10, 2023
Arterial Calcification, CD73 Deficiency Trial run by the NHLBI (Etidronate, MRI Scan)
Completed
- Arterial Calcification
- CD73 Deficiency
- Etidronate
- MRI Scan
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 9, 2022
Lung Cancer Circulating Tumor Cells
Not yet recruiting
- Non Small Cell Lung Cancer
- Sample
-
Nice, FranceCHU de Nice
Dec 5, 2022
Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)
Not yet recruiting
- Nephrotic Syndrome
- Rituximab Biosimilar ABP 798
- Daratumumab
-
Genova, ItalyIRCCS G. Gaslini
Jan 19, 2023
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma Trial in Los Angeles
Not yet recruiting
- Borderline Resectable Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Biospecimen Collection
- +9 more
-
Los Angeles, CaliforniaYonemoto,Lisa
Jan 13, 2023
CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)
Recruiting
- CD70-positive Advanced Urologic Neoplasms
- Anti-CD70 CAR-T cells
-
Shanghai, Shanghai, ChinaChanghai Hospital
Aug 11, 2023
Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Evan Syndrome
- Treatment
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023